RxDoctor Payments DataLook up a doctor →

Baldeep Pabla, MD

Gastroenterology · Nashville, TNNPI 1770921553

Payments from drug & device makers

$1,217,819in general payments, 2019–2025

Across 455 payments — averaging $2676.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$495K
  • Takeda Pharmaceuticals U.S.A., Inc.$467K
  • Janssen Research & Development, LLC$162K
  • F. Hoffmann-la Roche AG$41K
  • Lilly USA, LLC$26K
  • Johnson & Johnson$12K
  • plus $15K from 6 others

What the payments were for

  • Consulting fees$18,15533%
  • Speaking & faculty fees$23,67543%
  • Travel & lodging$8,23515%
  • Food & beverage$4,8559%
  • Education$700%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,217,819 in reported general payments places this provider in the 95th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$42,887
Medicare patients
187
Services billed
402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab80$2,244,023
RinvoqUpadacitinib95$717,119
Skyrizi On-BodyRisankizumab-Rzaa35$669,139
Humira(Cf) PenAdalimumab40$486,534
Omvoh PenMirikizumab-Mrkz22$210,149
Mesalamine27$14,278
Budesonide14$8,391
Balsalazide Disodium18$1,838
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl89$1,272
Mesalamine ErMesalamine15$1,030
Azathioprine27$962
Dicyclomine Hcl13$584
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl30$427
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl20$344
Pantoprazole Sodium16$254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$11,827$2,244,02380 claims
AbbVieRinvoq$495,418$717,11995 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →